Initiation, titration, and discontinuation - utilization of heart failure medicines in England (EVOLUTION HF UK)

25 August 2023 (17:15 - 17:50)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Ruiqi Zhang

Astrazeneca, London (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail

Statin and risk of dementia in patients with heart failure

Mrs Q. Ren (Hong Kong, HK)

Abstract Slides Video

Presentation thumbnail

Soluble guanylate cyclase in heart failure: A network meta-analysis and subgroup analyses of reduced and preserved ejection fraction.

Doctor M. Ibrahim (Flint, US)

Abstract Slides Video

Presentation thumbnail

Feasibility, efficacy and safety of early and rapid initiation of evidence-based treatment for patients with HFrEF- a real world experience of the "four drugs in four weeks" strategy

Doctor S. Sze (Leicester, GB)

Abstract Slides Video

Presentation thumbnail

Impact of pharmacological treatment for heart failure after myocardial recovery in arrhythmia-induced cardiomyopathy.

Mr L. Dominguez Rodriguez (Madrid, ES)

Abstract Slides Video

Presentation thumbnail

Timing of angiotensin receptor-neprilysin inhibitor initiation in patients with heart failure and reduced ejection fraction: data from the Swedish heart failure registry

Professor L. Lund (Stockholm, SE)

Abstract Slides Video

Access the full session

Session thumbnail

Pharmacological therapy in heart failure (2)

The Event

Event poster

ESC Congress 2023

25 August 2023 17:15 CET

You may be interested in

Congress Session

Pharmacotherapy

Congress Presentation

What does routinely-collected electronic health record data tell us about the use of heart failure medication among older people in Wales? Making progress but could do better

Congress Session

Insights from recent HFrEF trials 2

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources